Device Trial Radar · NCT07753005
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
176
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Aesculap AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.
Conditions
- Hemorrhage
- Gastrointestinal Hemorrhage
- Hemoptysis
- Postpartum Hemorrhage
Interventions
Embolization therapyDevice
Embolization of Thoracoabdominal Artery Bleeding (TAB), excluding "Cardiac blood vessels other than Pulmonary artery", "Endoscopic esophageal varices embolization operations", and "Pulmonary artery malformation".
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Success at 1 Month After Histoacryl® EmbolizationTime frame: 30 ± 10 days after index embolization procedure
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.